<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04154982</url>
  </required_header>
  <id_info>
    <org_study_id>CCM1006</org_study_id>
    <nct_id>NCT04154982</nct_id>
  </id_info>
  <brief_title>N-Acetylcysteine Protection Against Radiation Induced Cellular Damage</brief_title>
  <acronym>CARAPACE</acronym>
  <official_title>Cardiac Arrhythmia Catheter Ablation Procedures Guided by x-Ray Imaging: N-Acetylcysteine Protection Against Radiation Induced Cellular damagE (CARAPACE Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Catheter ablation procedures (CAPs) are first line treatment for a great variety of cardiac
      arrhythmias. CAPs require X-Ray imaging; consequently, CAPs cause ionizing radiation (IR)
      exposure for patients. Exposure to IR, even at low-doses, increases individual risk of
      developing cancer. IR cause DNA damage directly and, mostly, indirectly by formation of
      cellular free radicals. Furthermore different response to IR results from inherited variants
      in genes involved in DNA damage repair. N-acetylcysteine (NAC) is an aminoacid that can
      directly neutralize free radicals and increase antioxidant systems. Our preliminary data
      suggest that IR exposure in patients undergoing CAP deranges the oxidative stress status and
      the pre-procedure intravenous administration of NAC could decrease such abnormality.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CARAPACE is a prospective, randomized, single-blinded, parallel-arm monocenter study.
      Eligible patients undergoing CAP at the Arrhythmology Unit of Centro Cardiologico Monzino
      will be enrolled.

      The hypothesis driving our study, based on published literature and our preliminary data, is
      that administration of antioxidant agents, before cardiac procedures involving IR exposure,
      might prevent IR harmful effects on human tissues in terms of reduction of systemic oxidative
      stress status and, in parallel, of oxidative DNA damage.

      The antioxidant agent tested in our study is NAC. NAC is a well-tolerated and safe medication
      and it has antioxidant properties is based on three main mechanisms: 1) direct antioxidant
      effect, 2) glutathione (GSH) precursor action, and 3) its activity in breaking thiolated
      proteins.

      Another hypothesis to be tested is whether genes involved in DNA damage repair could explain
      the great variability in patient radiosensitivity to IR exposure and whether these genes
      could affect NAC protective/healing effects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">February 3, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 3, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Researchers, involved in the assessment of NAC efficacy, are blinded to randomization process; thus, they do not know whether the patients are in the NAC or in the control groups.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement of change in systemic oxidative stress (ratio between GSH oxidized form (GSSG) and GSH, 8-iso-prostaglandinF2α (8-iso-PGF2α) and 8-hydroxy-2-deoxyguanosine (8-OHdG)) and genomic DNA oxidative damage (percentage of DNA present in the tails).</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of change in systemic oxidative stress (GSSG/GSH, 8-iso-PGF2α and 8-OHdG) and genomic DNA oxidative damage (% DNA present in the tails of the comet assay) between the two groups (NAC versus no NAC) at the different time-points (T0 = before CAP, T1 = 3h after CAP, T2 = 24h after CAP, T3 = 48h after CAP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of change in systemic oxidative stress (GSSG/GSH, 8-iso-PGF2α and 8-OHdG) and genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (fluoroscopy time (FT), Dose Area Product (DAP) and effective dose (ED)).</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of change in systemic oxidative stress (GSSG/GSH, 8-iso-PGF2α and 8-OHdG) and genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (FT, DAP and ED) between the two groups (NAC versus no NAC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of change in genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (FT, DAP and ED) and inherited variants in genes involved in DNA damage repair.</measure>
    <time_frame>48 hours</time_frame>
    <description>Measurement of change in genomic DNA oxidative damage (% DNA present in the tails) related to IR dose (FT, DAP and ED) and inherited variants in genes involved in DNA damage repair between the two groups (NAC versus no NAC).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of change in the response to NAC administration related to inherited variants in genes involved in DNA damage repair.</measure>
    <time_frame>48 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">550</enrollment>
  <condition>Cardiac Arrhythmia</condition>
  <arm_group>
    <arm_group_label>Pharmacological treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with NAC prior to carrying out CAP.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard procedure</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients are not treated with NAC. No placebo treatment is performed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Acetyl cysteine</intervention_name>
    <description>1200 mg of NAC are intravenously administrated 1 hour prior to carrying out CAP.</description>
    <arm_group_label>Pharmacological treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's age &gt;18 years.

          -  Negative hCG pregnancy test (if appropriate).

          -  Indication to perform CAP guided by fluoroscopy (IR imaging).

          -  Ability and willingness to give informed consent and to comply with protocol.

        Exclusion Criteria:

          -  Any contraindication to CAP (such as, pregnancy and breastfeeding).

          -  Hypersensitivity to the active substance or to any of the excipients.

          -  Enrollment in another study that may interfere with CARAPACE study.

          -  Administration of an experimental drug within 30 days or 5 half-lives of the
             investigational drug.

          -  Chronic kidney disease (serum creatinine &gt;1.5 mg/dl).

          -  Acute/Chronic inflammatory disease.

          -  Antioxidant drugs intake over the previous 2 weeks.

          -  History of radiotherapy or chemotherapy in the last year.

          -  Any documented condition that, in PI's motivated judgement, makes the patient a poor
             candidate for the study.

          -  Computed tomography and/or coronary angiography within 5 days prior to baseline
             analysis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Michela Casella</last_name>
    <phone>+39025800</phone>
    <phone_ext>2738</phone_ext>
    <email>michela.casella@ccfm.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Valentina Catto</last_name>
    <phone>+39025800</phone>
    <phone_ext>2856</phone_ext>
    <email>valentina.catto@ccfm.it</email>
  </overall_contact_backup>
  <link>
    <url>http://doi.org/10.1016/j.jacc.2018.02.017</url>
    <description>Expert Consensus Document on Optimal Use of Ionizing Radiation in Cardiovascular Imaging</description>
  </link>
  <link>
    <url>http://doi.org/10.17226/11340</url>
    <description>National Research Council. 2006. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII Phase 2. Washington, DC: The National Academies Press.</description>
  </link>
  <reference>
    <citation>Turnu L, Porro B, Alfieri V, Di Minno A, Russo E, Barbieri S, Bonomi A, Dello Russo A, Tondo C, D'Alessandra Y, Cavalca V, Tremoli E, Colombo GI, Casella M. Does Fluoroscopy Induce DNA Oxidative Damage in Patients Undergoing Catheter Ablation? Antioxid Redox Signal. 2018 Apr 20;28(12):1137-1143. doi: 10.1089/ars.2017.7334. Epub 2017 Nov 27.</citation>
    <PMID>28938845</PMID>
  </reference>
  <reference>
    <citation>Heidbuchel H, Wittkampf FH, Vano E, Ernst S, Schilling R, Picano E, Mont L, Jais P, de Bono J, Piorkowski C, Saad E, Femenia F. Practical ways to reduce radiation dose for patients and staff during device implantations and electrophysiological procedures. Europace. 2014 Jul;16(7):946-64. doi: 10.1093/europace/eut409. Epub 2014 May 2.</citation>
    <PMID>24792380</PMID>
  </reference>
  <reference>
    <citation>Evans MD, Dizdaroglu M, Cooke MS. Oxidative DNA damage and disease: induction, repair and significance. Mutat Res. 2004 Sep;567(1):1-61. Review.</citation>
    <PMID>15341901</PMID>
  </reference>
  <reference>
    <citation>Andreassi MG, Foffa I, Manfredi S, Botto N, Cioppa A, Picano E. Genetic polymorphisms in XRCC1, OGG1, APE1 and XRCC3 DNA repair genes, ionizing radiation exposure and chromosomal DNA damage in interventional cardiologists. Mutat Res. 2009 Jun 18;666(1-2):57-63. doi: 10.1016/j.mrfmmm.2009.04.003. Epub 2009 Apr 22.</citation>
    <PMID>19393248</PMID>
  </reference>
  <reference>
    <citation>Huang A, Glick SA. Genetic susceptibility to cutaneous radiation injury. Arch Dermatol Res. 2017 Jan;309(1):1-10. doi: 10.1007/s00403-016-1702-3. Epub 2016 Nov 22. Review.</citation>
    <PMID>27878387</PMID>
  </reference>
  <reference>
    <citation>Cervelli T, Panetta D, Navarra T, Gadhiri S, Salvadori P, Galli A, Caramella D, Basta G, Picano E, Del Turco S. A New Natural Antioxidant Mixture Protects against Oxidative and DNA Damage in Endothelial Cell Exposed to Low-Dose Irradiation. Oxid Med Cell Longev. 2017;2017:9085947. doi: 10.1155/2017/9085947. Epub 2017 Aug 9.</citation>
    <PMID>28852434</PMID>
  </reference>
  <reference>
    <citation>Aldini G, Altomare A, Baron G, Vistoli G, Carini M, Borsani L, Sergio F. N-Acetylcysteine as an antioxidant and disulphide breaking agent: the reasons why. Free Radic Res. 2018 Jul;52(7):751-762. doi: 10.1080/10715762.2018.1468564. Epub 2018 May 9. Review.</citation>
    <PMID>29742938</PMID>
  </reference>
  <reference>
    <citation>Mu H, Sun J, Li L, Yin J, Hu N, Zhao W, Ding D, Yi L. Ionizing radiation exposure: hazards, prevention, and biomarker screening. Environ Sci Pollut Res Int. 2018 Jun;25(16):15294-15306. doi: 10.1007/s11356-018-2097-9. Epub 2018 Apr 29.</citation>
    <PMID>29705904</PMID>
  </reference>
  <reference>
    <citation>Squellerio I, Caruso D, Porro B, Veglia F, Tremoli E, Cavalca V. Direct glutathione quantification in human blood by LC-MS/MS: comparison with HPLC with electrochemical detection. J Pharm Biomed Anal. 2012 Dec;71:111-8. doi: 10.1016/j.jpba.2012.08.013. Epub 2012 Aug 23.</citation>
    <PMID>22947504</PMID>
  </reference>
  <reference>
    <citation>Turnu L, Di Minno A, Porro B, Squellerio I, Bonomi A, Manega CM, Werba JP, Parolari A, Tremoli E, Cavalca V. Assessing Free-Radical-Mediated DNA Damage during Cardiac Surgery: 8-Oxo-7,8-dihydro-2'-deoxyguanosine as a Putative Biomarker. Oxid Med Cell Longev. 2017;2017:9715898. doi: 10.1155/2017/9715898. Epub 2017 Jun 4.</citation>
    <PMID>28660009</PMID>
  </reference>
  <reference>
    <citation>Cavalca V, Minardi F, Scurati S, Guidugli F, Squellerio I, Veglia F, Dainese L, Guarino A, Tremoli E, Caruso D. Simultaneous quantification of 8-iso-prostaglandin-F(2alpha) and 11-dehydro thromboxane B(2) in human urine by liquid chromatography-tandem mass spectrometry. Anal Biochem. 2010 Feb 15;397(2):168-74. doi: 10.1016/j.ab.2009.10.014. Epub 2009 Oct 13.</citation>
    <PMID>19825360</PMID>
  </reference>
  <reference>
    <citation>Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007 Sep;81(3):559-75. Epub 2007 Jul 25.</citation>
    <PMID>17701901</PMID>
  </reference>
  <reference>
    <citation>Amadio P, Colombo GI, Tarantino E, Gianellini S, Ieraci A, Brioschi M, Banfi C, Werba JP, Parolari A, Lee FS, Tremoli E, Barbieri SS. BDNFVal66met polymorphism: a potential bridge between depression and thrombosis. Eur Heart J. 2017 May 7;38(18):1426-1435. doi: 10.1093/eurheartj/ehv655.</citation>
    <PMID>26705390</PMID>
  </reference>
  <reference>
    <citation>Casella M, Dello Russo A, Russo E, Catto V, Pizzamiglio F, Zucchetti M, Majocchi B, Riva S, Vettor G, Dessanai MA, Fassini G, Moltrasio M, Tundo F, Vignati C, Conti S, Bonomi A, Carbucicchio C, Di Biase L, Natale A, Tondo C. X-Ray Exposure in Cardiac Electrophysiology: A Retrospective Analysis in 8150 Patients Over 7 Years of Activity in a Modern, Large-Volume Laboratory. J Am Heart Assoc. 2018 May 22;7(11). pii: e008233. doi: 10.1161/JAHA.117.008233.</citation>
    <PMID>29789334</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 17, 2019</study_first_submitted>
  <study_first_submitted_qc>November 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 7, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Michela Casella</investigator_full_name>
    <investigator_title>Deputy of Heart Rhythm Center</investigator_title>
  </responsible_party>
  <keyword>Electrophysiology</keyword>
  <keyword>Arrhythmias</keyword>
  <keyword>Arrhythmia ablation</keyword>
  <keyword>Ionizing radiation risk</keyword>
  <keyword>Oxidative stress</keyword>
  <keyword>DNA damage biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

